A novel cancer cell and lysosome dual-targeted photosensitizer (PS) termed by BMP was developed for fluorescence imaging and photodynamic therapy (PDT). BMP consists of a porphyrin(Zn) core with appropriate singlet-triplet state distribution enables it to function as an imaging agent as well as a PS, a biotin moiety that can target cancer cells, and a morpholine group specific to lysosomes. Intracellular experiments demonstrated that the dual-targeted photosensitizer BMP could preferably accumulate in cancer cells and subsequently locate within lysosome organelles. Upon irradiation, BMP could generate red fluorescence emission (Φ_em = 6.3%) and singlet oxygen (¹O₂, Φ_Δ = 55%) for the dual functionality of cell imaging and PDT, respectively. Notably, BMP exhibited much higher photocytotoxicity toward cancer cells (A549 cells) compared to normal cells (BEAS-2B cells). Importantly, ¹O₂ produced by BMP induced oxidative damage of lysosomes, and subsequently triggered cell death of A549 cells, as evidenced by the loss of morphological integrity and cell rupture.

一种新型癌细胞和溶酶体双靶向光敏剂（PS）（称为BMP ）被开发用于荧光成像和光动力治疗（PDT）。BMP由具有适当单线态-三线态分布的卟啉 (Zn) 核心组成，使其能够充当显像剂以及 PS、可靶向癌细胞的生物素部分和溶酶体特异性的吗啉基团。细胞内实验表明，双靶向光敏剂BMP可以更好地在癌细胞中积累，并随后定位在溶酶体细胞器内。照射后，BMP可以产生红色荧光发射（Φ _em  = 6.3%）和单线态氧（¹ O ₂，​​Φ _Δ  = 55%），分别用于细胞成像和 PDT 的双重功能。值得注意的是，与正常细胞（BEAS-2B 细胞）相比，BMP对癌细胞（A549 细胞）表现出更高的光细胞毒性。重要的是，BMP产生的¹ O ₂诱导溶酶体氧化损伤，随后引发 A549 细胞的细胞死亡，表现为形态完整性的丧失和细胞破裂。